Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Upadacitinib Extended-Release Tablets belong to the immunosuppressive therapeutic class and are a selective Janus kinase (JAK) inhibitor. Unlike conventional non-selective JAK inhibitors, it preferentially inhibits JAK1, regulating multiple pro-inflammatory cytokine signalling pathways. The extended-release formulation delivers sustained drug exposure, enabling once-daily dosing with stable systemic concentration and favourable pharmacokinetic profile.

This formulation is indicated for the treatment of atopic dermatitis and rheumatoid arthritis in adult patients who have had an inadequate response or intolerance to prior therapy.

Specifications: 15 mg (expressed as upadacitinib). Packaging: 30 tablets per bottle.

Manufactured in full GMP compliance, the tablets conform to international quality standards, with stringent control over impurities, dissolution and stability. We guarantee stable supply, competitive pricing, end-to-end quality control and flexible technical support to facilitate your registration and formulation development.

As a targeted oral JAK1 inhibitor, it achieves rapid improvement of inflammatory symptoms with a convenient once-daily regimen. Widely recognised in rheumatology and dermatology clinical practice, it addresses the substantial global demand for targeted therapies for autoimmune and inflammatory diseases.

We are able to supply qualified finished dosage forms, offer technology transfer and other flexible cooperation models. We welcome your enquiries for further information and potential collaboration.